Vancouver – For 14 years, Vancouver resident Craig Elliott, who is living with primary progressive multiple sclerosis (PPMS), and his family have been waiting for a therapeutic advancement for the treatment of progressive MS and recently they experienced just that.
Craig, who is a Partner in an accounting firm and a father of two, ages 17 and 15, received his first infusion of ocrelizumab (Ocrevus) – the first drug on the market conditionally approved by Health Canada for treatment of early PPMS, a form of the disease characterized by a steady worsening of neurological function. Ocrevus is said to act as an immunomodulatory drug that targets and removes potentially harmful cells in people living with MS.
His wife Cindy, who is a practice consultant with Providence Health Care, said she and Craig could not be more excited about this new development that is happening just before the fourth annual Women Against MS luncheon taking place on November 22 in Vancouver where they will be in attendance.
FOURTH ANNUAL WAMS NETWORKING LUNCHEON
Thursday November 22, 2018 12:00PM to 2:30PM at the Fairmont Hotel Vancouver
Tickets: Individual $125
Table (10 seats) $1250
VIP $175
VIP “Circle of Influence” Tables (10 seats) $1750
For more information on this important event, or to buy the limited tickets left, visit: www.wamsbc.ca
